[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pediatric-crohns-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pediatric-crohns-disease":80},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100618647","modified-vs-standard-cded-evaluation-of-a-nordic-adaptation-of-nutritional-therapy-in-paediatric-crohns-disease-100618647",false,"NCT07334340","Modified vs Standard CDED: Evaluation of a Nordic Adaptation of Nutritional Therapy in Paediatric Crohn's Disease","Modified vs Standard Crohn´s Disease Exclusion Diet: Evaluation of a Nordic Adaptation of Nutritional Therapy in Paediatric Crohn's Diseas","N-CDED","Inclusion Criteria:\n\n* Children aged 6-18 years with recent (\\\u003C36 months) mild-to-severe CD diagnosis (defined as Paediatric Crohn's Disease Activity Index \\[PCDAI\\] 15-47.5)\n* Evidence of active inflammation (C-reactive protein \\[CRP\\] ≥ 0.5 mg\u002FdL, erythrocyte sedimentation rate \\[ESR\\] ≥ 20 mm\u002Fh, and\u002For faecal calprotectin \\[FCP\\] ≥ 200 mg\u002Fg during screening)\n* Stable use of medication other than steroids.\n\nExclusion Criteria:\n\n* Eating disorders,\n* Active extraintestinal manifestations\n* Use of systemic corticosteroids\n* Active perianal disease\n* Positive stool cultures for pathogens, parasites, or Clostridioides difficile\n* Fever \\>38.3°C\n* Documented cow's milk protein allergy\n* Diabetes, celiac disease and\u002For psychosocial difficulties.","ALL","6 Years","18 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"NA","The primary aim of this clinical trial is to evaluate the clinical effectiveness of the Nordic Crohn's Disease Exclusion Diet (Nordic CDED) in children with Crohn's disease, measured by remission rates, and to compare these outcomes with those reported for the original CDED in similar pediatric populations and study designs.\n\nThe secondary objectives are to assess whether the Nordic CDED can facilitate greater individualization of the diet, improve treatment adherence, and enhance quality of life.\n\nThe study seeks to answer the following key questions:\n\n* Does the Nordic CDED achieve the same clinical effectiveness as the original CDED?\n* Does the Nordic CDED improve adherence and quality of life in children with Crohn's disease? To address these questions, researchers will compare outcomes from children following the Nordic CDED with published results from similar studies of the original CDED, as well as with patients who were not treated with a dietary intervention.\n\nParticipant Involvement:\n\n* Follow the Nordic CDED for 20 weeks.\n* Attend clinic visits at weeks 2, 8, 14, 20, and 24 for checkups and tests.\n* Report adherence to the diet through food records.\n* Report quality of life at the beginning and end of the study",[28],"Pediatric Crohns Disease",[30,31,32,33,34,35,36],"Pediatric gastroenterology","Crohn´s Disease","Enteral nutrition","Nutritional therapy","whole food","nordic CDED","CDED","NOT_YET_RECRUITING","2026-01-05",{"date":40,"type":41},"2026-01-12","ACTUAL",{"date":43,"type":22},"2026-02-01",{"date":45,"type":22},"2030-01-01",{"name":47,"class":48},"Vastra Gotaland Region","OTHER_GOV",3,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":79},"100503999","autophagy-in-paediatric-crohns-disease-100503999","NCT05842564","Autophagy in Paediatric Crohn's Disease","Autophagic Activity Characterization in Pediatric Crohn's Disease","P-IBDphagy","Inclusion Criteria:\n\nFor Crohn's Disease group :\n\n* Age between 6 and 17 inclusive\n* Patients with a weight \\> 25 kg at the time of inclusion\n* Patients with Crohn's disease requiring ileocolonoscopy (diagnosis or follow-up)\n* Mild to severe Crohn's disease consistent with PCDAI disease activity score\n* Patients on nutritional therapy (Modulen\u002FModulife), corticosteroids, salicylic derivatives, immunosuppressants, biotherapies (anti-TNF, vedolizumab and ustekinumab) or without treatment\n* Consent form signed by the patient or the holder(s) of parental authority.\n* Affiliation to a social security scheme or beneficiaries of a similar scheme.\n\nFor Control group:\n\n* Between 6 and 17 years old included\n* Presenting a weight \\> 25 kg at the time of inclusion\n* Without a diagnosis of Crohn's disease\n* Requiring evaluation by ileoendoscopy\n* Consent form signed by the patient or the holder(s) of parental authority.\n* Affiliation to a social security scheme or beneficiaries of a similar scheme.\n\nExclusion Criteria:\n\n* Refusal to participate in the protocol\n* Intercurrent infection\n* Ongoing antibiotic treatment\n* Patient involved in another interventional study protocol including an exclusion period still in progress at pre-inclusion\n* Pregnant, parturient or breastfeeding women (on questioning)\n* Persons deprived of their liberty by a judicial or administrative decision\n* Persons subject to psychiatric care\n* Persons admitted to a health or social establishment for purposes other than research","17 Years",{"count":60,"type":22},70,[25],"Crohn's disease is a multifactorial complex disease resulting in a between microbiota and immune system. Indeed, GWAS (Genome-Wide Association Studies) association study pinpointed polymorphisms as genes susceptibility on more than 200 loci. Among them genes coding for proteins involved in autophagy machinery (i.e: ATG16L1, IRGM et NDP52). Autophagy is a ubiquitous intracellular mechanism mandatory for protein and microorganism recycling.\n\nSo far, the role of autophagy in gut inflammation and intestinal homeostasis in Crohn's disease patients is partially understand. Then, investigators plan to evaluate, on native cells, the autophagic flux in pediatric patients suffering of a Crohn's disease compare to controls.",[64,28],"Crohn Disease",[66,67,68],"Crohn's Disease","Autophagy","Polymorphism","2024-12-11",{"date":71,"type":41},"2024-12-12",{"date":73,"type":22},"2025-01",{"date":75,"type":22},"2027-04",{"name":77,"class":78},"Hospices Civils de Lyon","OTHER",1,"Pediatric Crohn's Disease"]